Free Trial

France allows visitors with Indian-made AstraZeneca vaccine

Visitors enjoy the view from the Eiffel Tower in Paris, Friday, July 16, 2021. The Eiffel Tower is reopening Friday for the first time in nine months, just as France faces new virus rules aimed at taming the fast-spreading delta variant. The "Iron Lady" was ordered shut in October as France battled its second surge of the virus. (AP Photo/Michel Euler)
Remove Ads

PARIS (AP) — France will allow international travelers who have had AstraZeneca’s Indian-manufactured vaccine into the country starting Sunday.

At the same time, France is tightening border checks to control the spread of the delta variant and protect hospitals, according to a statement from the prime minister Saturday.

The move to accept visitors vaccinated with AstraZeneca’s vaccine made by India’s Serum Institute came after a global outcry over the fact that the European Union’s COVID-19 certificate only recognizes AstraZeneca vaccines manufactured in Europe.

Several other EU countries already accept the Indian version, which is notably used in the U.K. and around Africa. The varied rules from each country have further complicated this summer's travel season. France still doesn't recognize vaccinations by Chinese or Russian vaccines, only those authorized by the EU drug regulator: those made by Pfizer/BioNTech, Moderna, Johnson&Johnson and AstraZeneca.

Starting Sunday, France will also start requiring anyone who isn't vaccinated arriving from Britain, Spain, Portugal, the Netherlands, Greece or Cyprus to present a negative test less than 24 hours old to cross French borders.

Tunisia, Indonesia, Cuba and Mozambique have now been added to France’s “red list” of countries with high virus risk, according to Saturday’s statement. However, France will now accept travelers from any red list countries if they are fully vaccinated.

France also shortened the time frame for when a person is considered fully vaccinated after the second dose, to one week instead of two.

As infections climb anew, French President Emmanuel Macron this week ordered all health workers to get vaccinated by Sept. 15 and announced that special COVID-19 passes will be required in all restaurants, bars, hospitals, shopping malls, trains, and planes. To get a pass, people must be fully vaccinated, have recently recovered from the virus, or have a fresh negative virus test.

Remove Ads

The measures have prompted record numbers of people to sign up for vaccinations — but have also prompted anger among some groups, and protests are planned in various French cities Saturday against them.

___

Follow AP’s pandemic coverage at:

https://apnews.com/hub/coronavirus-pandemic

https://apnews.com/hub/coronavirus-vaccine

https://apnews.com/UnderstandingtheOutbreak

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)
4.5242 of 5 stars
$163.01-0.8%3.04%24.51Moderate Buy$171.33
Compare These Stocks  Add These Stocks to My Watchlist 

Remove Ads

Featured Articles and Offers

Recent Videos

SMCI’s Rally Isn’t Over – Here’s Why It Could Hit $100!
7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads